LYON, France, Sept. 1, 2010 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, is pleased to announce that its Chief Financial Officer, Eric Soyer, was interviewed yesterday by The Wall Street Reporter. The interview provides a corporate overview of EDAP TMS and highlights the new Focal Therapy trend in the urology community to address prostate cancer. The interview also covers EDAP's market expansion of Ablatherm-High Intensity Focused Ultrasound (HIFU) into China and recent advancements with its Sonolith i-sys and Sonolith i-move, for which the company has submitted a 510(k) application for marketing clearance to the U.S. Food & Drug Administration.
Mr. Soyer discussed the current major shift to a new paradigm in the treatment of prostate cancer that is called "focal therapy" as opposed to current radical treatments of the prostate. There is a growing demand for less aggressive treatment options for prostate cancer while preserving patient quality of life. Focal therapy, which calls for a targeted, precise treatment and significantly reduces the side effects or complications, has the potential to be a perfect compromise. "This trend is a huge market opportunity for therapeutic ultrasounds, which indeed offer a unique blend of treatment accuracy, efficacy, and reduced morbidity. And we at EDAP, as one of the leaders in HIFU want to take advantage of that trend and leverage our prominent IP portfolio and technological expertise in the field."
Mr. Soyer further noted EDAP's potential opportunities in the lithotripsy space. EDAP's two state of the art technologies to treat urinary stones, Sonolith i-move and Sonolith i-sys, have been approved by European and Japanese officials respectively. In the U.S., we recently submitted the application for 510(k) marketing clearance to the FDA for the Sonolith i-move. Upon clearance, EDAP will then be well positioned to address all U.S. lithotripsy market segments.